PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan

Rhea-AI Summary

PTC Therapeutics (NASDAQ: PTCT) announced MHLW approval of Sephience (sepiapterin) in Japan for the treatment of children and adults living with phenylketonuria (PKU).

The Japanese label covers all ages and the full spectrum of disease severity. This is PTC's first product approval in Japan and follows approvals in the EU and US within less than six months, enabling a coordinated global launch. PTC said pricing discussions in Japan are expected to conclude in Q1 2026, with commercial launch occurring shortly thereafter.

Positive

• MHLW approval granted for Sephience in Japan
• Label covers all ages and full disease severity
• First product approval for PTC in Japan
• Approvals in EU, US, and Japan within six months

Negative

• Commercial launch dependent on pricing talks expected to conclude in Q1 2026

Key Figures

Pricing discussions timeline Q1 2026 Pricing discussions in Japan expected to conclude before product launch

Market Reality Check

$76.76 Last Close

Volume Volume 2619493 is modestly above the 20-day average of 2334263 (relative 1.12). normal

Technical Price 78.57 is trading above the 200-day MA at 56.58, reflecting a pre-existing uptrend.

Peers on Argus

Key biotech peers like TGTX and KRYS show modest gains (e.g., 3.4, 3.24), but no peers appear in the momentum scanner and PTCT’s 5.34% move looks more company-specific than sector-driven.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 18	Conference presentation	Neutral	-0.5%	Announcement of CEO presentation at J.P. Morgan Healthcare Conference.
Dec 01	Equity grants	Neutral	-7.9%	Inducement stock options and RSUs granted to new employees.
Nov 20	R&D day	Neutral	+1.1%	Planned R&D Day to showcase small molecule and inflammation platforms.
Nov 04	Earnings update	Positive	-0.3%	Q3 2025 revenue and net income with Sephience launch metrics.
Oct 31	Investor conferences	Neutral	+0.3%	Participation in multiple upcoming healthcare investor conferences.

Pattern Detected

Recent news has typically produced modest price moves, with one notable divergence where positive Q3 2025 earnings coincided with a small share price decline.

Recent Company History

Over the last few months, PTC has focused on investor outreach and pipeline visibility, including multiple conference appearances and an upcoming J.P. Morgan presentation on Jan. 12, 2026. Q3 2025 results showed revenue of $211.0M and net income of $15.9M, alongside the initial global launch of Sephience. Today’s Japan approval extends that launch footprint, building on earlier FDA and EC approvals highlighted in the Q3 2025 disclosures.

Market Pulse Summary

This announcement expands Sephience’s reach with approval in Japan for PKU patients of all ages and disease severities, complementing prior EU and U.S. approvals. It builds on Q3 2025 disclosures that highlighted Sephience’s initial global launch. Investors may watch how Japan pricing discussions, expected to conclude in Q1 2026, translate into uptake and revenue, while also considering recent insider selling activity and the stock’s position near its 52-week high.

Key Terms

phenylketonuria medical

"for the treatment of children and adults living with phenylketonuria (PKU)."

A rare inherited metabolic disorder in which the body cannot break down the amino acid phenylalanine, causing it to build up and potentially damage the brain if not detected and managed. It matters to investors because newborn screening, lifelong dietary management, prescription medical foods, enzyme therapies, and emerging gene or drug treatments create ongoing markets and regulatory milestones that can affect companies’ revenues and valuation. Think of it as a clogged filter that needs special maintenance to prevent harm.

pku medical

"for the treatment of children and adults living with phenylketonuria (PKU)."

An inherited metabolic condition in which the body cannot properly break down phenylalanine, an amino acid found in food, causing it to build up and potentially harm brain development if untreated; think of it as a factory line that can’t process one raw material, so the excess piles up. It matters to investors because routine newborn screening, lifelong specialized diets, medical foods and evolving drug or gene therapies create ongoing healthcare demand, regulatory pathways, and potential market opportunities tied to approvals, pricing and reimbursement.

sepiapterin medical

"Sephience™ (sepiapterin) has been approved by the Japanese Ministry"

Sepiapterin is a small natural molecule the body converts into tetrahydrobiopterin (BH4), a helper chemical needed to make certain brain chemicals and to keep blood vessels working properly. For investors, sepiapterin matters because therapies or diagnostics that raise or mimic its activity can affect neurological, cardiovascular and inflammatory conditions; tracking research, patents and clinical trials around it is like watching a key recipe ingredient — successful results can create new drug or diagnostic markets, while failures can halt those opportunities.

mhlw regulatory

"approved by the Japanese Ministry of Health, Labor and Welfare (MHLW)"

Japan’s Ministry of Health, Labour and Welfare (MHLW) is the national government agency that sets and enforces rules for public health, medicines and medical devices, workplace safety, and social welfare. For investors, MHLW decisions act like a country’s rulebook for companies in pharmaceuticals, medical devices, hospitals and employer-heavy industries—approvals, safety recalls, pricing policies or labor regulations can directly affect a firm’s sales, costs and legal risks.

AI-generated analysis. Not financial advice.

– Indication includes all ages and the full spectrum of disease severity –
– First Japan product approval for PTC –

WARREN, N.J., Dec. 22, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that Sephience™ (sepiapterin) has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of children and adults living with phenylketonuria (PKU). The label includes individuals of all ages and the full spectrum of disease severity.

"The approval of Sephience in Japan is an important milestone for Japanese patients living with PKU as well as for PTC," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "I am proud that we have been able to achieve approvals for Sephience in the EU, US and Japan within less than six months, allowing for a true global launch. Our team in Japan is fully built and excited to bring Sephience to any individual who may benefit."

PTC will now engage in pricing discussions which are expected to conclude in Q1 2026, with launch occurring shortly thereafter. 

About Sephience™ (sepiapterin)
Sephience™ is indicated for the treatment of adult and pediatric patients with phenylketonuria (PKU). Sephience is a natural precursor of the enzymatic co-factor BH4, a critical co-factor for phenylalanine hydroxylase (PAH). Through its mechanism of action, Sephience is able to effectively reduce blood phenylalanine (Phe) levels and has the potential to treat a broad range of PKU patients. Sephience is approved in the European Union / European Economic Area region, the United States and Japan.

About Phenylketonuria
Phenylketonuria (PKU) is a rare, inherited metabolic disease, characterized by the body's inability to break down an essential amino acid called phenylalanine (Phe) and which can result in neurological and other symptoms. If left untreated or poorly managed, Phe can build up to harmful levels in the body. This causes severe and irreversible disabilities, such as permanent intellectual disability, seizures, delayed development, memory loss, and behavioral and emotional problems. Newborns with PKU initially do not have any symptoms, but symptoms are usually progressive, and damage caused by toxic levels of Phe in the first few years of life is irreversible. Diagnosis of PKU usually takes place during newborn screening programs. There are an estimated 58,000 people living with PKU globally.

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders.

For More Information:

Investors: 
Ellen Cavaleri
+1 (615) 618-6228
ecavaleri@ptcbio.com

Media: 
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com 

Forward-Looking Statement 
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; expectations with respect to Sephience, including timing of commercialization; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.

PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to Sephience, including any regulatory submissions and potential approvals, commercialization and the potential achievement of regulatory and sales milestones and contingent payments that PTC may be obligated to make; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; and the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Sephience.

The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-approval-of-sephience-sepiapterin-for-the-treatment-of-children-and-adults-living-with-phenylketonuria-pku-in-japan-302647819.html

SOURCE PTC Therapeutics, Inc.

FAQ

What did PTC Therapeutics (PTCT) announce on December 22, 2025 about Sephience in Japan?

PTC announced MHLW approval of Sephience (sepiapterin) to treat children and adults with PKU, covering all ages and disease severities.

Does the Sephience Japan label for PTCT cover pediatric and adult PKU patients?

Yes. The Japan label explicitly includes individuals of all ages and the full spectrum of disease severity.

When is Sephience expected to launch commercially in Japan for PTCT (PTCT)?

PTC said pricing discussions are expected to finish in Q1 2026, with launch occurring shortly after.

Is Sephience PTC's first product approval in Japan (PTCT)?

Yes. The company said this is PTC's first product approval in Japan.

How does the Japan approval affect PTC's global strategy for Sephience (PTCT)?

The approval completes regulatory approvals in the EU, US, and Japan within less than six months, supporting a coordinated global launch.